Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone
Brief Summary: This study is being carried out to see if dapagliflozin in addition to glimepiride (sulphonylurea) is effective and safe in treating patients with type 2 diabetes when compared to glimepiride alone.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Intervention Type: DRUG; Name: dapagliflozin; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: metformin hydrochloride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: pioglitazone hydrochloride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Glimepiride
C: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg/Placebo | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg/Canagliflozin 150mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Canagliflozin 300mg/Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Canagliflozin 300mg/Canagliflozin 150mg; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Canagliflozin 300mg; Assigned to Arm(s): 003
D: Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glyburide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A

Answer: A